Article

17 Aug 2006

Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[Presentation by Daniel Rosan begins at 54:30; refers to Abbott Laboratories, Bristol-Myers Squibb, Merck, Gilead Sciences, Wyeth]

Timeline

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Date:

4 Mar 2014

Content Type:

Company Response
[PDF] Benchmarking AIDS: 2006 Year End Update

Date:

30 Nov 2006

Content Type:

Article
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Date:

13 Sep 2006

Content Type:

Company Response
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Date:

13 Sep 2006

Content Type:

Company Response
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Date:

13 Sep 2006

Content Type:

Company Response
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Date:

12 Sep 2006

Content Type:

Article
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Date:

6 Sep 2006

Content Type:

Company Response
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Date:

6 Sep 2006

Content Type:

Company Response
Reclaman mayor compromiso de las farmacéuticas

Date:

31 Aug 2006

Content Type:

Article

Available languages: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Date:

23 Aug 2006

Content Type:

Company Response
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Date:

23 Aug 2006

Content Type:

Company Response
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Date:

23 Aug 2006

Content Type:

Company Response
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Date:

17 Aug 2006

Content Type:

Article
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Date:

17 Aug 2006

Content Type:

Article
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Date:

14 Aug 2006

Content Type:

Article
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Date:

1 Aug 2006

Content Type:

Company Response
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Date:

1 Aug 2006

Content Type:

Company Response
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Date:

8 Jan 2006

Content Type:

Company Response
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Date:

8 Jan 2006

Content Type:

Company Response

View full story

Load more View less

Business & Human Rights
Resource Centre

Gulf energy explorer: Renewables, rights and risks

10 years on: A call to concrete action for a powerful legally binding instrument - Webinar series

Rush to renewables: Toward migrant worker rights and a just energy transition in the Gulf

New research reveals risk of egregious migrant worker abuse in Gulf renewable energy supply chains

Effective participation of affected communities in the Treaty process – a perspective from Latin America

Challenges and opportunities for the participation of affected communities in the Treaty process - a perspective from Latin America

Our database: Using filters

International Advisory Network

Business & Human Rights Resource Centre

Gulf energy explorer: Renewables, rights and risks

10 years on: A call to concrete action for a powerful legally binding instrument - Webinar series

Rush to renewables: Toward migrant worker rights and a just energy transition in the Gulf

New research reveals risk of egregious migrant worker abuse in Gulf renewable energy supply chains

Effective participation of affected communities in the Treaty process – a perspective from Latin America

Challenges and opportunities for the participation of affected communities in the Treaty process - a perspective from Latin America

Our database: Using filters

International Advisory Network

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Timeline

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.